The pharmacological management of severe influenza infection–‘existing and emerging therapies’

Expert Review of Clinical Pharmacology

Volumn 10, Issue 1, 2017, Pages 81-95

  Mc Mahon, Aisling ^a   Martin Loeches, Ignacio ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

H1N1; influenza; influenza virus bacteria co infection; oseltamivir; peramivir; steroids; zanamivir

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; ARBIDOL; AVI 1700; CORTICOSTEROID; DAS 181; FAVIPIRAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANINAMIVIR; MACROLIDE; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; NEUTRALIZING ANTIBODY; NITAZOXANIDE; OSELTAMIVIR; PERAMIVIR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROSTAGLANDIN SYNTHASE INHIBITOR; RIBAVIRIN; RIMANTADINE; UNCLASSIFIED DRUG; ZANAMIVIR; NEW DRUG;

ANTIVIRAL THERAPY; CHINESE HERB; HUMAN; IMMUNOMODULATION; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS; META ANALYSIS (TOPIC); MIXED INFECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT INDICATION; ANIMAL; ANTIVIRAL RESISTANCE; DRUG DESIGN; EPIDEMIC; HEALTH; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; SEVERITY OF ILLNESS INDEX; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; DRUGS, INVESTIGATIONAL; GLOBAL HEALTH; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; OSELTAMIVIR; SEVERITY OF ILLNESS INDEX;

EID: 85008249238     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1080/17512433.2017.1255550     Document Type: Review

References (137)

1. Centre for Disease Control and Prevention (CDC), Pink book–influenza. [cited 2016 July5]. Available from:https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/flu.pdf
2. Paul Glezen W, Schmier JK, Kuehn CM, et al. The burden of influenza B:a structured literature review. Am J Public Health. 2013 Mar;103(3):e43–e51.
3. Tran D, Vaudry W, Moore D, et al., Members of the Canadian Immunization Monitoring Program Active. Hospitalization for influenza A versus B. Pediatrics. 2016 Aug 17;138:e20154643–e20154643. [Epub ahead of print]
4. Centers for Disease Control and Prevention (CDC) Resources for pandemic influenza. [cited 2016 Aug25]. Available from:http://www.cdc.gov/flu/pandemic-resources/index.htm
5. Potter CW., A history of influenza. J Appl Microbiol. 2001 Oct;91(4):572–579.
6. Beveridge WI. The chronicle of influenza epidemics. Hist Philos Life Sci. 1991;13(2):223–234.
7. World Health Organization (WHO). Fact sheet on influenza. [cited 2016 July5]. Available from:http://www.who.int/mediacentre/factsheets/fs211/en/
8. Thompson WW, Moore MR, Weintraub E, et al. Estimating influenza-associated deaths in the United States. Am J Public Health. 2009;99(Suppl 2):S225–30. doi:10.2105/AJPH.2008.151944.
9. Fowlkes AL, Arguin P, Biggerstaff MS, et al. Epidemiology of 2009 pandemic influenza A (H1N1) deaths in the United States, April–July 2009. Clin Infect Dis. 2011;52 (Suppl 1):S60–8. doi:10.1093/cid/ciq022.
10. Taylor G, Abdesselam K, Pelude L, et al. Epidemiological features of influenza in Canadian adult intensive care unit patients Epidemiol. Infect. 2016;144:741–750.
11. Skarbinski J., Jain S,Bramley A, et al. Hospitalized Patients with 2009 pandemic influenza A (H1N1) Virus Infection in the United States—September–October 2009. Clin Infect Dis. 2011;52(Suppl 1):S50–9. doi:10.1093/cid/ciq021.
12. Martin-Loeches I, Díaz E, Vidaur L, et al., H1N1 SEMICYUC/REIPI/CIBERES Working group. Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients. Crit Care. 2011;15(6):R286.• Postpandemic increase of ICU mortality.
13. WHO Guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. Geneva:World Health Organization; 2010 Feb. Available from:https://www.ncbi.nlm.nih.gov/books/NBK138515/.
14. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1–26.
15. Dunning J, Openshaw P. Severe influenza:clinical features and treatment options. Curr Respir Med Rev. 2012;8:208–227.
16. Pan American Health Organization/WHO (2014) Operational guidelines for sentinel severe acute respiratory infection (SARI) surveillance. [cited 2016 July25]. Available from:http://www.paho.org/revelac-i/wp content/uploads/2015/10/2015-cha-opera- tional-guidelines-sentinel-sari.pdf
17. Sakr Y, Ferrer R, Reinhart K, et al.; IC-GLOSSARI Investigators and ESICM Trials Group. The Intensive Care Global Study on Severe Acute Respiratory Infection (IC-GLOSSARI):a multicenter, multinational, 14-day inception cohort study. Intensive Care Med. 2016;42:817–828.
18. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children diagnosis, treatment, chemoprophylaxis, and institutional outbreak management:clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1003.
19. Muthuri SG, Myles PR, Venkatesan S, et al. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-10 influenza A(H1N1) pandemic:a systematic review and metaanalysis in hospitalized patients. J Infect Dis. 2013 Feb;207(4):553–563.
20. Rodriguez A, Diaz E, Martin-Loeches I, et al. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother. 2011;66:1140–1149.
21. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis. 2012;55(9):1198–1204.
22. Muthuri SG, Venkatesan S, Myles PR, et al.; PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection:a meta-analysis of individual participant data. Lancet Respir Med. 2014 May;2(5):395–404.
23. Gasparini R, Amicizia D, Lai PL, et al. Compounds with anti-influenza activity:present and future of strategies for the optimal treatment and management of influenza. Part I:influenza life-cycle currently available drugs. J Prev Med Hyg. 2014;55:69–85.
24. Davies BE. Pharmacokinetics of oseltamivir:an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother. 2010;65(Suppl 2):ii5–ii10.
25. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014 Apr 10;(4):CD008965. doi:10.1002/14651858.CD008965.pub4.
26. Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir:a comprehensive review. Drug Saf. 2008;31(12):1097–1114.
27. Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ. 2010;182(4):357–363.
28. Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza A and B infections. Clin Infect Dis. 2013;57(11):1511–1519.
29. South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza:double blind randomised controlled trial. BMJ. 2013;346:f3039.
30. Jittamala P, Pukrittayakamee S, Tarning J, et al. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects. Antimicrob Agents Chemother. 2014;58(3):1615–1621.
31. Thorne-Humphrey LM, Goralski KB, Slayter KL, et al., 2009 OPTIMO Study Group. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). J Antimicrob Chemother. 2011 Sep; 66(9):2083–2091.
32. Eyler RF, Heung M, Pleva M, et al. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Pharmacotherapy. 2012 Dec;32(12):1061–1069.
33. Kromdijk W, Sikma MA, Van Den Broek MPH, et al. Pharmacokinetics of oseltamivir carboxylate in critically ill patients:each patient is unique. Intensive Care Med. 2013;39:977–978.
34. Mulla H, Peek GJ, Harvey C, et al. Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support. Anaesth Intensive Care. 2013 Jan;41(1):66–73.
35. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet. 2013;381:2273–2279.
36. Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2009;11:100–105.
37. Van Der Vries E, Stittelaer KJ, Van Amerongen G, et al. Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog. 2013;9(5):1–11.
38. Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults:a meta-analysis of randomised controlled trials. Lancet. 2015;385:1729–1737.
39. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection:a meta-analysis of individual participant data. Lancet Respir Med. 2014;2:395–404.
40. Muthuri SG, Venkatesan S, Myles PR, et al. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia:an individual participant data meta-analysis. Influenza Other Respi Viruses. 2016;10(3):192–204.
41. Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet. 1999;36(Suppl 1):1–11.
42. Food and Drug Administration (FDA). Important drug warning.[cited 2016 July15]. Available from:http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM186224.pdf
43. Marty FM, Man CY, Van Der Horst C, et al. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza:an open-label, multicenter, single-arm, phase II study. J Infect Dis. 2014;209:542–550.
44. Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med. 2010;362:88–89.
45. De Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis. 2014;59(12):e172-85.
46. Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54:4568–4574.
47. Yamashita M. Laninamivir and its prodrug, CS-8958:long-acting neuraminidase inhibitors for the treatment of influenza. Antivir Chem Chemother. 2010;21:71–84.
48. Watanabe A, Sc C, Kim MJ, et al., MARVEL Study Group. Longacting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza:a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51:1167–1175.
49. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS- 8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010;54:2575–2582.
50. Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitorresistant variants. Antimicrob Agents Chemother. 2001;45(12):3403–3408.•• Landmark article to show effectivity of antiviral drugs.
51. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis. 2009;15(4):552–560.
52. Kelso A, Hurt AC. The ongoing battle against influenza:drug-resistant influenza viruses:why fitness matters. Nat Med. 2012;18:1470–1471.
53. Hurt AC, Hardie K, Wilson NJ, et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med. 2011;365(26):2541–2542.
54. Storms AD, Gubareva LV, Su S, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010–2011. Emerg Infect Dis. 2012;18:308–311.
55. Pizzorno A, Bouhy X, Abed Y, et al. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis. 2011;203:25–31.
56. Van Der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med. 2010;363:1381—2.•• Increase resistant pandemic influenza A (H1N1) virus after the second year of pandemics.
57. Eshaghi A, Patel SN, Sarabia A. Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child. Emerg Inf Dis. 2011;17(8):1472–1474.
58. Hurt AC, Holien JK, Parker M, et al. Zanamivir resistant influenza viruses with a novel neuraminidase mutation. J Virol. 2009;83(20):10366–10373.
59. Hurt AC, Lee RT, Leang SK, et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill. 2011;16(23):pii:19884.
60. McKimm-Breschkin JL. influenza neuraminidase inhibitors:antiviral action and mechanisms of resistance. Influ Other Respir Viruses. 2013;7(Suppl 1):25–36.
61. Dapat C, Suzuki Y, Saito R, et al. Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs. Emerg Infect Dis. 2010;16:493–496.
62. Ison MG, Gubareva LV, Atmar RL, et al. Recovery of drug-resistant influenza virus from immunocompromised patients:a case series. J Infect Dis. 2006;193:760–4.
63. Li TCM, Chan MCW, Lee N. Clinical implications of antiviral resistance in influenza. Viruses. 2015;7(9):4929–4944.
64. Garg S, Moore Z, Lee N, et al. A cluster of patients infected with I221V influenza B virus variants with reduced oseltamivir susceptibility–North Carolina and South Carolina, 2010–2011. J Infect Dis. 2013;207:966–973.
65. Sleeman K, Guo Z, Barnes J, et al. R292K substitution and drug susceptibility of influenza A(H7N9) viruses. Emerg Infect Dis. 2013;19:1521–1524.
66. Pozo F, Lina B, Andrade HR, et al., Community Network of Reference Laboratories for Human influenza in Europe. Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe. J Clin Virol. 2013 May; 57(1):5–12.
67. World Health Organisation (WHO). Weekly Epidemiological Record (WER). 2012 Sep 28. cited 2016 Oct 26;87(39):369–380. Available from:http://www.who.int/wer/6372012/wer8739/en/
68. Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther. 2012;17(1 Pt B):159–173.• Neuraminidase resistance mechanisms.
69. Ison MG, Hayden FG. Therapeutic options for the management of influenza. Curr Opin Pharmacol. 2001;1:482–490.
70. Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults:systematic review. Lancet. 2006;367:303–313.
71. Alves Galvão MG, Rocha Crispino Santos MA, Alves Da Cunha AJL. Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database Syst Rev. 2012 Jan 18;(1):CD002745.
72. Abed Y, Govette N, Boivin G. Generation and characterization of recombinant influenza A (H1n1) viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother. 2005 Feb;49(2):556–559.
73. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis. 2007 Jul 15;196(2):249–257.
74. Mustaquim D, Bishop A, Epperson S, et al. CDC Update:influenza activity–United States, 2009–10 season. Morbidity and Mortality Weekly Report (MMWR). 2010;59:901–908.
75. Crotty S, Cameron C, Andino R. Ribavirin’s antiviral mechanism of action:lethal mutagenesis? J Mol Med (Berl). 2002;80:86–95.
76. Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N Engl J Med. 2009;361:1713–1714.
77. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013 Nov;100(2):446–454.
78. Boltz DA, Aldridge JR, Webster RG, et al. Drugs in development for influenza. Drugs. 2010;70(11):1349–1362.
79. Boriskin YS, Leneva IA, Pecheur EI, et al. Arbidol:a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008;15(10):997–1005.
80. Huang L, Zhang L, Liu Y, et al. Arbidol for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2015 Jan 29;(1):CD011489.
81. Ison MG, Gnann JW, Jr, Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther. 2003;8:183–190.
82. Duval X, Van Der Werf S, Blanchon T, et al. Efficacy of oseltamivirzanamivir combination compared to each monotherapy for seasonal influenza:a randomized placebo-controlled trial. PLoS Med. 2010;7:e1000362.
83. Seo S, Englung JA, Nguyen JT. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection:safety and pharmacokinetics. Antivir Ther. 2013;18(3):377–386.
84. Hoopes JD, Driebe EM, Kelley E, et al. Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS ONE. 2011;6(12):e29778.
85. Kim WY, Suh GY, Huh JW. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother. 2011;55(12):5703–5709.
86. F, Marty, CY, Man, C, van der Horst, et al. Safety, tolerability and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza:An open-label, multicenter, single-arm, phase II study. J Infect Dis. 2014;209:542–550.
87. Hudson C. A, Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily in the treatment of hospitalized adults and adolescents with influenza. Clinicaltrials.gov identifier NCT01231620. [cited 2016 Sep11]. Available from:http://www.gsk-clinicalstudyregister.com/files2/gsk-114373-clinical-study-result-summary.pdf
88. Brennan BJ, Davies B, Cirrincione-Dall G, et al. Safety, tolerability, and pharmacokinetics of intravenous oseltamivir:single- and multiple-dose phase I studies with healthy volunteers. Antimicrob Agents Chemother. 2012 Sep;56(9):4729–4737.
89. Muñoz FM, Anderson EJ, Deville JG, et al. Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies. Int J Clin Pharmacol Ther. 2015 Jul;53(7):531–540.
90. Karsch K, Chen X, Miera O, et al. Pharmacokinetics of oral and intravenous oseltamivir treatment of severe influenza B virus infection requiring organ replacement therapy. Eur J Drug Metab Pharmacokinet. 2016 Mar 19. [Epub ahead of print].
91. Várkonyi I, Chappey C, Giraudon M, et al. A part-randomized study of intravenous oseltamivir in adolescents and adults. Eur J Clin Microbiol Infect Dis. 2015;34:1181.
92. Baranovich T, Jones JC, Russier M, et al. The hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced acute respiratory distress syndrome. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2118–2131.
93. Haffizulla J, Hartman A, Hoppers M, et al., for the US Nitazoxanide influenza Clinical Study Group. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza:a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2014;14:609–618.
94. Rossignol JF, La Frazia S, Chiappa L, et al. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem. 2009;284:29798–29808.
95. Belardo G, La Frazia S, Cenciareli O, et al. A novel potential anti-influenza drug, acting in synergism with neuraminidase inhibitors [Internet]. Paper presented at:49th Infectious Disease Society of America Annual Meeting:New approaches to anti-viral therapy; Boston (MA); 2011 Oct 20–23. [cited 2016 July 18]. Available from:https://idsa.confex.com/idsa/2011/webprogram/Paper31075.html
96. Rossignol JF. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza. Clinicaltrials.gov identifier NCT01610245. [cited 2016 July18]. Available from:https://clinicaltrials.gov/ct2/show/NCT01610245
97. Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother. 2006;50:1470–1479.
98. Moss RB, Hansen C, Sanders RL, et al. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis. 2012;206:1844–1851.
99. Salvatore M, Satlin MJ, Jacobs SE, et al. DAS181 for treatment of parainfluenza virus infections in hematopoietic stem cell transplant recipients at a single center. Biol Blood Marrow Transplant. 2016 May;22(5):965–970.
100. Ansun Biopharma Inc. Randomized, Double-blind, Placebo-controlled Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza. Clinicaltrials.gov identifier NCT01740063. [cited 2016 July 18] Available from:https://clinicaltrials.gov/ct2/show/NCT01740063
101. Byrn RA, Jones SM, Bennett HB, et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother. 2015 Mar;59(3):1569–1582.
102. Vertex Press Release. VX-787 showed significant antiviral activity and reduced the severity and duration of influenza symptoms in phase 2 challenge study. [cited 2016 July18]. Available from:http://investors.vrtx.com/releasedetail.cfm?releaseid=744857
103. Vertex Pharmaceuticals Inc. A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combination With Oseltamivir for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects. Clinicaltrials.gov identifier NCT02342249. [cited 2016 July18]. Available from:https://clinicaltrials.gov/ct2/show/NCT02342249
104. Wollacott AM, Boni MF, Kristy J, et al. Safety and upper respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza A outbreaks. EBioMedicine. 2016;5:147–155.
105. [cited 2016 July19]. Available from:https://clinicaltrials.gov/ct2/show/NCT02468115
106. Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333:850–856.
107. Nakamura G, Chai N, Park S, et al. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe. 2013;14:93–103.
108. Henry Dunand CJ, Leon PE, Kaur K, et al. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest. 2015;125:1255–1268.
109. Li GM, Chiu C, Wrammert J, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci USA. 2012;109:9047–9052.
110. Wu Y, Cho M, Shore D, et al. A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus. Nat Commun. 2015;6:7708.
111. Krammer F, Palese P. influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol. 2013;3:521–530.
112. Iversen PL, Schnell F, Crumley S, et al. Post exposure efficacy of AVI-7100 against influenza A in mouse and ferret infection models. [cited 2016 July18]. Available from:https://www.escmid.org/escmid_publications/escmid_elibrary/materil?mid=4950
113. Davey RT, National Institute of Allergy and Infectious Diseases (NIAID). A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of AVI-7100 in Healthy Subjects. Clinicaltrials.gov identifier NCT01747148. [cited 2016 July19]. Available from:https://clinicaltrials.gov/ct2/show/NCT01747148
114. Thomas BJ, Porritt RA, Hertzog PJ, et al. Glucocorticosteroids enhance replication of respiratory viruses:effect of adjuvant interferon. Sci Rep. 2014;4:7176.
115. Diaz E, Martin-Loeches I, Canadell L, et al.; H1N1 SEMICYUC-CIBERES-REIPI Working Group (GETGAG). Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza. J Infect. 2012(64):311e318.
116. Martin-Loeches I, Lisboa T, Rhodes A, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med. 2011;37:272–283.• Deleterious effect of steroids.
117. Bermejo-Martin JF, Kelvin DJ, Eiros JM, et al. Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains. J Infect Developing Countries. 2009;3:159e61.
118. Martin-Loeches I, Bermejo-Martin JF, Valles J, et al. Macrolide based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia. Intensive Care Med. 2013;39:693–702.
119. Tleyjeh IM, Kashour T, Hakim FA, et al. Statins for the prevention and treatment of infections. Arch Intern Med. 2009;169:1658–1667.
120. Belser JA, Szretter KJ, Katz JM, et al. Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice. Virology. 2013;439:42–46.
121. An SC, Xu LL, Li FD, et al. Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic. Med Hypotheses. 2011;77:1054–1057.
122. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections:a multistate study. J Infect Dis. 2012 Jan 1;205(1):13–19.
123. Khandaker G, Rashid H, Chow MYK, et al. Statins for influenza and pneumonia. Cochrane Protocol. [cited 2016 July20]. Available from:http://www.cochrane.org/CD008916/ARI_statins-for-influenza-and-pneumonia
124. Lee SM, Gai WW,Cheung TK, et al. Antiviral activity of a selective COX-2 inhibitor NS-398 on avian influenza H5N1 infection. Influenza Other Respi Viruses. 2011;5(Sup pl. 1):230–251.
125. Zheng BJ, Chan KW, Lin YP, et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A. 2008;105(23):8091–8096.
126. Carey MA, Bradbury JA, Rebolloso YD, et al. Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. PLoS ONE. 2010;5(7):e11610.
127. Moseley CE, Webster RG, Aldridge JR. Original article:peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respi Viruses. 2010;4(5):307–311.
128. Budd A, Alleva L, Alsharifi M, et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother. 2007;51(8):2965–2968.
129. Aldridge JJR, Moseley CE, Boltz DA, et al. TNF/iNOSproducing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A. 2009;106(13):5306–5311.
130. Wang C, Cao B, Liu QQ, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza:a randomized trial. Ann Intern Med. 2011;155:217–225.
131. Jiang L, Deng L, Wu T. Chinese medicinal herbs for influenza. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD004559.
132. Martin-Loeches I, Sanchez-Corral A, Diaz E, H1N1 SEMICYUC Working Group. Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus. Chest. 2011;139(3):555–562.
133. Chertow DS, Memoli MJ. Bacterial coinfection in influenza A grand rounds review. JAMA. 2013;309(3):275–282.
134. Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mortality in the United States:increase of Staphylococcus aureus coinfection. Pediatrics. 2008 Oct;122(4):805–811.
135. Rice TW, Rubinson L, Uyeki TM, et al.; for the NHLBI ARDS Network. Critical illness from 2009 pandemic influenza A (H1N1) virus and bacterial co-infection in the United States. Crit Care Med. 2012 May;40(5):1487–1498.
136. Martin-Loeches I, J Schultz M, Vincent JL, et al. Increased incidence of co-infection in critically ill patients with influenza. Intensive Care Med. 2016 Oct 5. [Epub ahead of print].•• Increase coinfection rates.
137. Wauters J, Baar I, Meersseman P, et al. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients:a retrospective study. Intensive Care Med. 2012;38:1761–1768.